Primary Sclerosing Cholangitis
102
23
30
36
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
20 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
9.8%
10 terminated out of 102 trials
78.3%
-8.3% vs benchmark
12%
12 trials in Phase 3/4
56%
20 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 36 completed trials
Clinical Trials (102)
TruGraf Liver Gene Expression Serial Test
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
LEOPARD Training and Validation Data Collection Study
LEOPARD Prospective Validation Cohort 1
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Detoxification of the Liver In PSC (Dolphin)
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Primary Sclerosing Cholangitis in Children
CM-101 in PSC Patients -The SPRING Study
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Vancomycin for Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
A Pilot Study Examining Diet in Primary Sclerosing Cholangitis
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study